Novartis Trileptal subpoena
Executive Summary
Allegations of off label-promotion of Novartis' anti-epileptic Trileptal (oxcarbazepine) are under investigation by Philadelphia U.S. Attorney's Office, the company says July 14. The attorney's office issued a subpoena May 26 and is understood to have opened parallel civil and criminal investigations pursuant to privacy regulations under the Health Insurance Portability and Accountability Act. Boston Assistant U.S. Attorney Michael Loucks (now first assistant) has predicted that federal prosecutors are likely to bring lawsuits against drug companies that violate HIPAA's privacy provisions (1"The Pink Sheet" Nov. 3, 2003, p. 42)...
Allegations of off label-promotion of Novartis' anti-epileptic Trileptal (oxcarbazepine) are under investigation by Philadelphia U.S. Attorney's Office, the company says July 14. The attorney's office issued a subpoena May 26 and is understood to have opened parallel civil and criminal investigations pursuant to privacy regulations under the Health Insurance Portability and Accountability Act. Boston Assistant U.S. Attorney Michael Loucks (now first assistant) has predicted that federal prosecutors are likely to bring lawsuits against drug companies that violate HIPAA's privacy provisions (1 (Also see "Off-Label Promotion Prosecutors Watch Second-Generation Indications" - Pink Sheet, 3 Nov, 2003.), p. 42).... |